Chiranjit Dutta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chiranjit Dutta has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ananya Chatterjee
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur-741246, India
1 shared publication - Archana Tripathi
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur-741246, India
1 shared publication - Argha Mario Mallick
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur-741246, India
1 shared publication - Asmita Mukherjee
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur- 741246, West Bengal, India
1 shared publication Dandan Su
Institut Européen des Membranes Adaptive Supramolecular Nanosystems Group University of Montpellier ENSCM, CNRS Place Eugène Bataillon, CC 047 F‐34095 Montpellier France
1 shared publication- Gavin William Collie
Discovery Sciences
1 shared publication
Latest Publications
- Open Access
- 30 May 2024
- Published by Wiley in Small Science
- Vol. 4 (8) , 2300352
Innovative Self‐Assembly of 15‐Mer Chimeric α‐Peptide–Oligourea Foldamers toward Cl−‐Selective Ion Channels
Constructing artificial ion channels is a challenging task. Herein, the de novo design of transmembrane ion channels made up of amphiphilic peptide–oligourea chimeric helices is described. They consist of an oligourea segment (7‐mer) attached to the C‐terminus of a short peptide (8‐mer). Mass spectrometry (MS) and transmission electron microscopy (TEM) analyses show that in an aqueous solution, two of these chimeras (HPU‐E and HPU‐N) independently form defined oligomeric structures. TEM also shows that they form fiber bundles. The third related chimera HPU‐F does not oligomerize (MS) but forms spherical nanostructures (TEM). HPU‐E and HPU‐N exhibit anion transport activity across lipid bilayers via antiport mechanism (HPU‐N > HPU‐E). The anion selectivity of HPU‐N is Cl−>NO3− > Br−>SCN− > I− > AcO−>F−, which can be due to anion binding within the channels rather than size exclusion. Patch‐clamp data support HPU‐N's Cl− selectivity (PCl−/PI− = 3.26). X‐ray crystal structure (1.77 Å) of HPU‐N reveals well‐packed α‐helices, and cryo‐electron microscopy data shows the formation of nanotubes (13.7 Å diameter pores) and transmembrane channels. The study shows that α‐peptide–oligourea‐based de novo design can yield unique bioactive molecules with defined structures and functions.
- 30 May 2024
- Published by Wiley in Small Science
- Vol. 4 (8) , 2300352
Open AccessInnovative Self‐Assembly of 15‐Mer Chimeric α‐Peptide–Oligourea Foldamers toward Cl−‐Selective Ion Channels
Constructing artificial ion channels is a challenging task. Herein, the de novo design of transmembrane ion channels made up of amphiphilic peptide–oligourea chimeric helices is described. They consist of an oligourea segment (7‐mer) attached to the C‐terminus of a short peptide (8‐mer). Mass spectrometry (MS) and transmission electron microscopy (TEM) analyses show that in an aqueous solution, two of these chimeras (HPU‐E and HPU‐N) independently form defined oligomeric structures. TEM also shows that they form fiber bundles. The third related chimera HPU‐F does not oligomerize (MS) but forms spherical nanostructures (TEM). HPU‐E and HPU‐N exhibit anion transport activity across lipid bilayers via antiport mechanism (HPU‐N > HPU‐E). The anion selectivity of HPU‐N is Cl−>NO3− > Br−>SCN− > I− > AcO−>F−, which can be due to anion binding within the channels rather than size exclusion. Patch‐clamp data support HPU‐N's Cl− selectivity (PCl−/PI− = 3.26). X‐ray crystal structure (1.77 Å) of HPU‐N reveals well‐packed α‐helices, and cryo‐electron microscopy data shows the formation of nanotubes (13.7 Å diameter pores) and transmembrane channels. The study shows that α‐peptide–oligourea‐based de novo design can yield unique bioactive molecules with defined structures and functions.
- 30 June 2022
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 17 (16) , e202200451
Emerging Approaches for Enabling RNAi Therapeutics
RNA interference (RNAi) is a primitive evolutionary mechanism developed to escape incorporation of foreign genetic material. siRNA has been instrumental in achieving the therapeutic potential of RNAi by theoretically silencing any gene of interest in a reversible and sequence‐specific manner. Extrinsically administered siRNA generally needs a delivery vehicle to span across different physiological barriers and load into the RISC complex in the cytoplasm in its functional form to show its efficacy. This review discusses the designing principles and examples of different classes of delivery vehicles that have proved to be efficient in RNAi therapeutics. We also briefly discuss the role of RNAi therapeutics in genetic and rare diseases, epigenetic modifications, immunomodulation and combination modality to inch closer in creating a personalized therapy for metastatic cancer. At the end, we present, strategies and look into the opportunities to develop efficient delivery vehicles for RNAi which can be translated into clinics.
- 30 June 2022
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 17 (16) , e202200451
Emerging Approaches for Enabling RNAi Therapeutics
RNA interference (RNAi) is a primitive evolutionary mechanism developed to escape incorporation of foreign genetic material. siRNA has been instrumental in achieving the therapeutic potential of RNAi by theoretically silencing any gene of interest in a reversible and sequence‐specific manner. Extrinsically administered siRNA generally needs a delivery vehicle to span across different physiological barriers and load into the RISC complex in the cytoplasm in its functional form to show its efficacy. This review discusses the designing principles and examples of different classes of delivery vehicles that have proved to be efficient in RNAi therapeutics. We also briefly discuss the role of RNAi therapeutics in genetic and rare diseases, epigenetic modifications, immunomodulation and combination modality to inch closer in creating a personalized therapy for metastatic cancer. At the end, we present, strategies and look into the opportunities to develop efficient delivery vehicles for RNAi which can be translated into clinics.